Rejuvenation Technologies is a venture-backed biotech startup company out of Stanford University developing anti-aging therapeutics. Rejuvenation’s founders invented their lead compound, TERT mRNA. TERT mRNA extends telomeres in days sufficiently to reverse years of telomere shortening during aging. Rejuvenation hit their 2019 seed round preclinical milestones in 2020 showing that TERT mRNA-based telomere extension reduces fibrosis and extends survival in mice. Now with their upcoming Series A round Rejuvenation aims to achieve IND approval for their first formulation in 2022 and expand their pipeline to target other indications and aging mechanisms.
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):